Compare Neurocrine Biosciences Inc (NBIX) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Starbucks Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 7.4× Neurocrine Biosciences Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Starbucks Corp for 190 Days on average.
| NBIX | SBUX | |
|---|---|---|
Market Cap | $14.36B | $106.26B |
Volume | 1,237,180 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $108.55 |
52-Week Low | $123.10 | $78.46 |
Typical Hold Time | 23 Days | 190 Days |
Enterprise Value | $14.37B | $125.08B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Starbucks (SBUX) trades at $93.21, down 0.4% on the day, amid a bearish technical signal and recent store closure announcements. The stock shows mixed earnings performance with Q1 and Q2 2026 beats but a Q4 2025 miss, while 2025 revenue grew to $37.18B with a net income margin of 5.17%. Analyst consensus is a Buy with a $115.50 price target, but technical indicators suggest near-term pressure with support at $89 and resistance at $96.
The outlook for SBUX hinges on its turnaround strategy execution, including portfolio optimization through store closures. Upside potential exists from analyst targets, but risks include labor relations, competitive pressures, and macroeconomic sensitivity. The stock's high P/E of 53.88 indicates growth expectations must be met for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
